News | Implantable Cardioverter Defibrillator (ICD) | June 14, 2016

Feasibility Study Results Support Medtronic Extravascular ICD Therapy

System in development places ICD leads under rib cage, outside heart and veins

June 14, 2016 — Medtronic plc announced results from several feasibility studies evaluating a new approach to implantable cardioverter defibrillator (ICD) therapy at Cardiostim/EHRA Europace 2016, the World Congress in Electrophysiology and Cardiac Techniques, in Nice, France.

The Medtronic EV-ICD System, which currently is in development and not available for use or sale, is a new approach to ICD therapy, with leads placed outside the heart and veins, and under the rib cage. The studies presented are the first to evaluate the new concept, and the results demonstrate that "extravascular" lead placement may provide the same benefits achieved with conventional ICDs, including pacing the heart in patients at risk of dangerous heart rhythms.

"Physicians are interested in an ICD with a similar device footprint and performance profile of conventional ICDs — but without the need for vascular access — and these study results are encouraging," said Francis Murgatroyd, M.D., consulting cardiologist and director of cardiac electrophysiology at King's College Hospital in London. "We look forward to further assessing the benefits of the EV-ICD approach in order to make this important advancement a reality for physicians and patients worldwide."

The Medtronic EV-ICD system in development consists of an implanted device, a newly designed lead and procedure tools to guide the efficient delivery of the system. Like conventional ICDs, the system is designed to deliver life-saving electrical shocks to protect patients from sudden cardiac death; to deliver anti-tachycardia pacing (ATP) to pace the heart out of potentially life-threatening heart rhythms that can lead to sudden cardiac death; and to provide post-shock pacing. Similar to transvenous ICD systems, the Medtronic EV-ICD is projected to have longevity of approximately 10 years and an expected device volume of approximately 33 cc. In addition to these potential benefits, the EV-ICD approach is designed to prevent the rare but potentially serious risks that can occur when leads are implanted inside the vasculature and the heart.

The data presented at Cardiostim 2016 assessed the feasibility of pacing and defibrillation with leads outside the heart and under the rib cage:

  • Substernal Pacing Acute Clinical Evaluation (SPACE) studied 26 patients from eight sites in the United States and Canada, with preliminary data demonstrating that pacing is possible from a lead placed outside the heart and under the rib cage (also referred to as extravascular space), with the majority of patients achieving consistent and appropriate ventricular pacing results;
  • Results from a prospective, nonrandomized study of 16 patients scheduled to undergo a midline sternotomy and implant of an ICD demonstrated that defibrillation is possible with the lead placed under the rib cage, and energy levels that are consistent with conventional ICDs;
  • Anatomical analysis of computed tomography (CT) scans from 68 patients with cardiovascular disease found that, despite considerable variations in patient anatomy, placement of a lead between the rib cage and heart should be feasible with limited interactions with the lungs; and
  • A final abstract demonstrated that the EV-ICD approach requires lower energy (defibrillation thresholds) than subcutaneous devices, and comparable energy to conventional ICDs.

Sudden cardiac arrest is an abrupt loss of heart function that can result in death if not treated within minutes. Conventional ICDs involve leads (thin wires) connected to the heart to deliver shocks or ATP that restore normal heart rhythms. ICDs are proven to be 98 percent effective in treating dangerous ventricular arrhythmias that can lead to sudden cardiac arrest.

For more information: www.medtronic.com


Related Content

News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
Subscribe Now